Xiang Tan Shi

Researchers are evaluating the effects of traditional Chinese medicine products on hair loss (alopecia) and gray hair (canities) in a 6-month randomized, double-blind, placebo-controlled trial. The study plans to enroll 152 adults aged 18 to 60 years who have hair loss and some with gray hair. The trial aims to assess changes in hair shedding, hair count, hair density, and hair color over the study period. Participants will be randomly assigned to one of four groups receiving different combinations of oral capsules and hair tonic treatments, including active products and placebos, to be used for 24 weeks. Each group will receive either VitaGreen Capsule A or B combined with VitaGreen Tonic, or placebos for capsules and/or tonic. Throughout the 24 weeks, participants will apply the treatments as directed. Participants will attend three in-person visits for assessments including hair-related tests and photographs at the start, week 12, and week 24. Outcomes measured include hair shedding count, local hair count and density, percentages of vellus and terminal hair, and scoring of hair changes from images. A subgroup of 10 participants with gray hair per group will have additional assessments focused on hair color changes. All clinical data will be recorded for analysis.

Researchers are evaluating the effect of a triple therapy inhaler called BGF MDI containing budesonide, glycopyrronium, and formoterol fumarate compared with a dual therapy inhaler called GFF MDI containing glycopyrronium and formoterol fumarate in people with Chronic Obstructive Pulmonary Disease (COPD) who have a higher risk of heart and lung problems. This Phase III randomized, double-blind, parallel group study takes place at multiple centers and focuses on cardiopulmonary outcomes in these patients. Participants receive either the BGF MDI 320/14.4/9.6 micrograms twice daily or the GFF MDI 14.4/9.6 micrograms twice daily. The treatments are inhaled using metered dose inhalers. The study compares these two therapies over time to see how they affect the time until the first severe heart or lung event occurs. The study design ensures that neither participants nor researchers know which treatment is given to reduce bias. During the study, participants will have regular visits to the study site or virtual visits to complete assessments. Researchers will monitor lung function, symptoms, and blood tests, including blood eosinophil counts and COPD assessment test scores. The main outcome measured is the time to the first severe cardiac or COPD event, with follow-up lasting up to three years. Safety and adherence to treatment will also be closely observed throughout the study period.

Researchers are evaluating the immune response and safety of a single dose of the RSVPreF3 OA investigational vaccine in Chinese adults aged 18 to 59 years who are at increased risk of respiratory syncytial virus (RSV) disease. This Phase 3, randomized, controlled, observer-blind study compares immune responses in this group to those of older adults aged 60 years and above from a previous study. The goal is to understand how well the vaccine stimulates immunity and assess its safety and side effects in this younger adult population at risk. Participants will receive one dose of either the RSVPreF3 OA vaccine or a placebo, both administered as an injection into the deltoid muscle of the non-dominant arm. The study focuses on observing the immune response one month after vaccination by measuring RSV-A and RSV-B neutralizing antibody levels. The vaccine and placebo administration and follow-up procedures are carefully controlled and monitored. During the study, participants will be closely monitored for immune responses through blood tests measuring neutralizing antibodies against RSV types A and B 31 days after vaccination. Safety and reactogenicity will also be assessed throughout the trial. The total duration involves vaccination and follow-up visits to ensure comprehensive evaluation of the vaccine's effects and participant safety.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Researchers are investigating how changes in hemoglobin levels relate to hospital readmissions and death from any cause in patients with heart failure. This study focuses on patients treated with dapagliflozin, a drug previously shown to reduce worsening heart failure events and cardiovascular death, compared to a placebo. The aim is to understand whether improving anemia is an important factor for the benefits of dapagliflozin in heart failure patients. This is a phase 4, prospective, randomized, double-blind study where participants receive either dapagliflozin 10 mg once daily or a placebo 10 mg once daily. All patients continue to receive standard therapy for heart failure. The study tracks changes in hemoglobin levels and records heart failure-related hospital readmissions and deaths over follow-up periods at 3 months, 6 months, and 1 year. Participants will be monitored through these scheduled follow-ups to assess hemoglobin changes and clinical outcomes. The main outcome measured is the combined number of hospital admissions for heart failure and all-cause mortality within one year. The study includes adult men and women aged 18 to 100 years who have heart failure with reduced ejection fraction and elevated heart failure biomarkers.

Researchers are evaluating the safety and effectiveness of giving tirofiban early to patients who have received tenecteplase for acute ischemic stroke. This phase 3 study addresses the problem of reocclusion that happens in 14-34% of patients after thrombolysis, likely due to platelet activation. The goal is to see if adding tirofiban soon after tenecteplase can reduce this risk and improve patient outcomes. Participants will be randomly assigned to receive either a continuous intravenous infusion of tirofiban or a placebo. The infusion starts at 0.3 micrograms per kilogram per minute for 30 minutes, followed by 0.075 micrograms per kilogram per minute for 47.5 hours, beginning within 4 to 24 hours after tenecteplase treatment. Aspirin and/or clopidogrel placebos are given orally 24 hours after tenecteplase, with actual antiplatelet therapy starting at 44 hours and continuing until 90 days after randomization. During the study, participants are monitored for neurological function changes and safety. The main outcome measured is excellent functional recovery 90 days after randomization. The study includes neurological assessments, imaging tests, and laboratory evaluations. Participants are followed for 90 days to observe treatment effects and any adverse events.

Stroke is the second leading cause of death worldwide, with ischemic stroke being the most common type. The current best treatment for acute ischemic stroke is intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) given within 4.5 hours of symptom onset. However, some patients experience stroke progression or early blood vessel reocclusion after thrombolysis, which worsens neurological function and outcomes. This is believed to be caused by increased platelet activation after thrombolysis, which peaks within the first 2 hours. This clinical trial is testing whether starting oral aspirin early after intravenous thrombolysis can improve functional outcomes without causing more bleeding problems. Patients are randomly assigned to receive either 300 mg aspirin tablets or matching placebo tablets as soon as possible after enrollment. If swallowing is difficult, tablets can be crushed and given through a nasogastric tube. Both groups receive best medical management according to guidelines. The study is a Phase 3, multicenter, randomized, placebo-controlled trial. Participants will be followed for 90 days after stroke to measure their functional recovery using the modified Rankin scale (mRS). Researchers will check if patients have a good outcome defined as an mRS score of 0 or 1 at 90 days. During the study, patients undergo assessments including neurological exams and imaging to confirm eligibility and monitor safety. The trial aims to determine if early aspirin treatment after thrombolysis is safe and can help prevent neurological decline and improve recovery.

Researchers are evaluating the effectiveness, safety, and tolerability of subcutaneous lunsekimig compared to a placebo in adults aged 40 to 80 years with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This Phase 2b/Phase 3, parallel, 3-arm study focuses on participants who have a history of COPD with an eosinophilic profile and have not achieved control with current treatments. Eligible participants will receive either lunsekimig or a matching placebo through subcutaneous injections over a randomized treatment period of approximately 48 weeks. The study involves three periods: an initial screening period lasting up to 4 weeks, followed by the 48-week treatment period, and finally an 8-week follow-up period. The total study duration may last up to 60 weeks. During the study, participants will be regularly assessed for the annualized rate of moderate-to-severe COPD exacerbations from baseline up to 48 weeks. Researchers will monitor safety, tolerability, and treatment effects through various evaluations throughout the treatment and follow-up periods. Participant involvement includes completing assessments and receiving scheduled injections as part of the study protocol.

Researchers are investigating the role of endovascular thrombectomy in patients who have suffered an acute ischemic stroke with an extra-large infarct core, which means a very large area of brain damage. While previous studies have shown benefits of thrombectomy for patients with large strokes, the effects on those with infarct volumes greater than 100 mL or very low ASPECTS scores (0 to 2) remain unclear. This trial aims to evaluate the safety and effectiveness of mechanical thrombectomy in this specific patient group. The study compares two treatments: endovascular thrombectomy combined with medical management versus medical management alone. Medical management includes intravenous thrombolysis, antiplatelet therapy, and/or anticoagulation. Endovascular thrombectomy involves techniques like stent retriever use, local aspiration, angioplasty, or stenting to remove the blood clot. Patients will be randomly assigned to either receive both treatments or only medical management to assess differences in outcomes. Participants will be adults aged 18 or older who have had an acute ischemic stroke with large vessel occlusion and meet specific imaging criteria. They will be followed for at least 90 days after randomization. Researchers will evaluate their recovery using the Modified Rankin Scale score to measure functional outcomes. The study includes detailed monitoring through imaging and clinical assessments to ensure safety and to understand the benefits of each treatment approach.

Researchers are evaluating the effectiveness and safety of intravenous recombinant human tenecteplase (rhTNK-tPA) in adults who have had an acute ischemic stroke caused by a large vessel blockage. This phase III, randomized, double-blind, placebo-controlled trial focuses on patients presenting between 4.5 and 24 hours after their last known normal state. The study aims to determine if rhTNK-tPA improves blood flow before thrombectomy and leads to better functional outcomes at 90 days, while also monitoring risks like symptomatic brain bleeding and death. Participants will be randomly assigned to receive either a single intravenous bolus of rhTNK-tPA (0.25 mg/kg, up to 25 mg) or a placebo. All participants will undergo endovascular thrombectomy to remove the blockage. Imaging tests such as CT angiography or MRI angiography will confirm stroke location and viable brain tissue before treatment. Follow-up imaging at 24 hours will assess reperfusion, with neurological evaluations conducted at days 5-7 and functional status checked at 90 days. During the study, patients will be closely monitored for safety outcomes including brain hemorrhage and mortality. Researchers will measure functional independence using the modified Rankin Scale at 90 days as the primary outcome. Additional assessments include early reperfusion rates, stroke severity, and brain infarct size. An independent committee will oversee data safety and outcome assessments throughout the trial, which plans to enroll 820 participants to detect meaningful clinical differences.